title: To BRCA or Not to PALB.
authors.affiliation: University of Manchester; The Christie National Health Service Foundation Trust, Manchester, United Kingdom Mairead.McNamara@christie.nhs.uk.
authors.forename: Mairead G
authors.initials: MG
authors.lastname: McNamara
authors.affiliation: University of Manchester; The Christie National Health Service Foundation Trust, Manchester, United Kingdom.
authors.forename: Angela
authors.initials: A
authors.lastname: Lamarca
authors.affiliation: University of Manchester; The Christie National Health Service Foundation Trust, Manchester, United Kingdom.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Hubner
authors.affiliation: University of Manchester; The Christie National Health Service Foundation Trust, Manchester, United Kingdom.
authors.forename: Juan W
authors.initials: JW
authors.lastname: Valle
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D005260:Female; D018095:Germ-Line Mutation; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D010793:Phthalazines / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D019313:BRCA1 Protein; D024682:BRCA2 Protein; D010793:Phthalazines; D010879:Piperazines